Concepts in Development

ALTG 15/004 BR.34: A randomized trial of durvalumab (MEDI4736) and tremelimumab ± platinum-based chemotherapy in patients with high-risk advanced or metastatic (stage IIIB/IV) squamous or non-squamous NSCLC – L Seymour (CCTG), B Hughes (ALTG)

 

  • The overall objective of this trial is to determine if durvalumab + tremelimumab, ± first-line platinum-based combined chemotherapy, improves overall survival in patients with incurable advanced or metastatic NSCLC
  • Planned global recruitment 300 (ANZ 100)
  • Likely to progress in 2017 pending outcome of ongoing discussions between ALTG and CCTG

ALTG 16/002 FCR: Fear of Cancer Recurrence in patients with early stage NSCLC – S McLachlan

 

  • Protocol in development
  • Project grant submitted March 2017 to NHMRC, Cancer Australia and Cancer Council NSW
  • If successful, anticipated study start late 2018

ALTG 16/003 Optimal duration of treatment with immunotherapy (advanced NSCLC) – K O’Byrne

 

  • Project grant unsuccessful in 2016; under review

ALTG 16/007 ALKTERNATE: Single arm phase 2 trial in ALK-rearranged NSCLC alTERNATing lortatinib with crizotinib after progression on first line crizotinib – N Pavlakis

 

  • This study aims to identify whether a fixed, ongoing alternating schedule of lorlatinib with crizotinib results in ongoing disease control and suppression of detectable innate or acquired ALK gene resistance mutations in blood; and to determine if ALK gene resistance mutations in circulating tumour DNA can be used to identify participants developing resistance before progression is clinically evident
  • Planned recruitment 40 patients from 15 sites
  • Concept submitted and under review for funding

ALTG 16/008 NINA: Phase 2 single arm study of nintedanib in combination with avelumab as second line therapy in patients with advanced NSCLC – N Pavlakis

 

  • This study aims to assess the activity of nintedanib combined with avelumab after patients have progressed on prior platinum doublet chemotherapy in NSCLC
  • Planned recruitment 40 from 16 sites
  • Concept submitted and under review for funding

ALTG 16/009 ILLUMINE: A Phase 2 study of durvalumab plus tremelimumab in patients with relapsed EGFR mutant NSCLC – C Lee

 

  • This study aims to evaluate the efficacy and tolerability of combination durvalumab plus tremelimumab in patients with relapsed EGFR mutant NSCLC
  • Planned recruitment 50 from 15 sites
  • Concept submitted and under review for funding

ALTG 16/010 LungCare: A multicentre randomised controlled trial comparing primary care vs hospital-based follow-up following surgical lobectomy for NSCLC – F Brims

 

  • Grant application submitted March 2017 to NHMRC, Cancer Australia and Cancer Council

ALTG 16/012 STIMULI: A Phase 2 trial of consolidation with nivolumab and ipilimumab in limited-stage SCLC after chemo-radiotherapy – European Thoracic Oncology Platform (ETOP) study – P Mitchell (ALTG)

 

  • To evaluate if chemo-radiotherapy and prophylactic cranial irradiation followed by nivolumab and ipilimumab consolidation have better outcome (PFS and OS) compared to patients treated with chemo-radiotherapy and prophylactic cranial irradiation without nivolumab and ipilimumab consolidation
  • Planned global recruitment 260
  • Study has recruited 84 patients to date with recruitment estimated to continue to 2019
  • Preliminary feasibility circulated to ALTG sites Dec 2016
  • Under consideration for ALTG participation

ALTG 17/001 Active surveillance in patients with MPM: a prospective single arm phase II trial – A Nowak

 

  • Project grant submission planned for 2018
  • If successful, anticipated study start late 2018
Upcoming Events
  1. TACT Board Teleconference (closed)

    August 28 - August 29
  2. ESMO 2017 Congress, Madrid Spain

    September 8 - September 12
  3. ***UPDATED*** 3rd ALTG Preceptorship in Lung Cancer, Melbourne VIC

    September 22 @ 12:00 pm - September 23 @ 5:00 pm UTC+10
  4. TACT General Assembly (closed), Yokohama Japan

    October 15
  5. 18th WCLC, Yokohama Japan

    October 15 - October 18